A tesamorelin and sermorelin stack pairs two GHRH analogs that hit the same receptor. Here's what the evidence says about stacking, dosing, and safety.
Tesamorelin and sermorelin are both growth hormone-releasing hormone (GHRH) analogs, so a tesamorelin and sermorelin stack means taking two peptides that act on the exact same receptor. Because they compete for one binding site instead of triggering two separate pathways, most researchers treat the combination as redundant, and no published human trial has tested the pair together. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, while sermorelin has no current FDA-approved product in the United States.
What Tesamorelin and Sermorelin Each Do
Tesamorelin is a stabilized 44-amino-acid GHRH analog. It binds pituitary GHRH receptors, increases natural growth hormone pulses, raises IGF-1, and in clinical trials reduced visceral adipose tissue in people with HIV-associated lipodystrophy. Sermorelin is a shorter fragment, GHRH(1-29), that does the same basic job with a much shorter window of activity.
Neither peptide is growth hormone itself. Both tell the pituitary to release more of the body's own GH, which is why they are grouped together as secretagogues.
| Feature | Tesamorelin | Sermorelin |
|---|---|---|
| FDA status | Approved (Egrifta WR) for HIV-associated lipodystrophy | No current FDA-approved product; compounded with a prescription |
| Receptor target | GHRH receptor | GHRH receptor |
| Half-life | Roughly 26 to 38 minutes | Roughly 10 to 20 minutes |
| Typical studied dose | 1 to 2 mg once daily, subcutaneous | 100 to 300 mcg at night, subcutaneous |
| Most common side effects | Injection site reactions, joint pain, swelling | Flushing, headache, injection site reactions |
Does a Tesamorelin and Sermorelin Stack Make Pharmacological Sense?
Tesamorelin and sermorelin bind the same GHRH receptor, so using them together creates competition for one target rather than adding a second signal. In practical terms, that means the pair is unlikely to produce a bigger GH pulse than a well-dosed single GHRH analog.
People searching for tesamorelin and sermorelin together usually want to know whether the combination raises growth hormone output beyond what either peptide does alone. Based on the shared mechanism, the expected answer is no, and not in any reliable way.
Two conclusions are worth stating plainly:
- Tesamorelin and sermorelin compete for the same pituitary receptor, so stacking them does not create a two-pathway effect.
- No clinical trial has evaluated a tesamorelin and sermorelin stack in humans, so dosing claims circulating online are extrapolation rather than evidence.
How GHRH Analogs Are Usually Combined
The combinations that appear in research and clinical practice typically pair a GHRH analog with a different class of peptide, most often a ghrelin mimetic such as ipamorelin or hexarelin. One agent drives GHRH signaling while the other drives a separate receptor pathway, which is the logic behind most stacking protocols.
| Combination | Second pathway? | Typical rationale |
|---|---|---|
| Tesamorelin + sermorelin | No, same GHRH receptor | Redundant; no human trial data |
| Tesamorelin + ipamorelin | Yes, ghrelin receptor | Classic GHRH plus GHRP pairing |
| Sermorelin + CJC-1295 | No, both GHRH analogs | Longer activity from CJC-1295 |
| Tesamorelin + MOTS-c | Yes, mitochondrial signaling | Different endpoint, not GH stacking |
| BPC-157 + sermorelin | Yes, repair versus GH release | Separate goals, occasionally paired |
A sermorelin and cjc-1295 stack is a common talking point because CJC-1295 stays active far longer, though both compounds still act on the same GHRH receptor. Conversations about the tesamorelin and cjc-1295 stack run into that same limitation.
Forum write-ups such as the tesamorelin and ipamorelin stack reddit threads describe the two-receptor approach that most people in the space actually follow. A tesamorelin and mots-c stack is a different idea entirely, since MOTS-c targets mitochondrial function rather than growth hormone release.
Someone focused on tissue recovery rather than hormone output may look into a bpc-157 and sermorelin stack, where the two peptides act on unrelated systems and are not expected to compete. Combining tesamorelin with a GLP-1 or GIP agonist such as tirzepatide is a separate question about appetite and glucose control, not about GHRH receptor signaling.
Dosing Considerations in Research
Doses studied in the literature are not the same as doses discussed on forums. Tesamorelin's approved regimen is 2 mg subcutaneously once daily, and its trials used 1 mg or 2 mg daily for 26 to 52 weeks. Sermorelin research doses typically fall between 100 mcg and 300 mcg at bedtime, since natural GH release peaks during deep sleep.
- Timing: GHRH analogs are usually given at night, before sleep, on an empty stomach.
- Frequency: once daily for both peptides in most published protocols.
- Monitoring: IGF-1, fasting glucose, and A1c are the standard labs.
- Duration: tesamorelin trials ran 6 to 12 months; long-term stacking data does not exist.
Any decision about dosing belongs with a licensed healthcare professional who can review labs, medications, and contraindications.
Safety, Side Effects, and Legal Status
Tesamorelin is a prescription medication in the United States and is approved only for HIV-associated lipodystrophy. Sermorelin is not FDA-approved for any indication and is dispensed only through compounding pharmacies with a prescription.
- Both peptides raise IGF-1, and persistently elevated IGF-1 is a marker doctors monitor rather than ignore.
- Reported side effects include injection site reactions, joint or muscle pain, fluid retention, headache, and numbness or tingling in the hands.
- Tesamorelin has been associated with changes in blood sugar, and GHRH analogs are generally avoided in people with active cancer.
- Sermorelin may trigger antibody formation in some users, which can reduce its effect over time.
Because GHRH analogs alter hormone signaling, anyone considering them should speak with a physician, especially with a history of cancer, diabetes, or pituitary disease.
Bottom Line
The tesamorelin and sermorelin stack is a same-receptor combination that most evidence-based sources consider unnecessary. If the goal is stronger GH signaling, a GHRH analog plus a ghrelin mimetic is the more defensible pairing; if the goal is visceral fat reduction, tesamorelin alone has the clinical data. In every case, prescription status, IGF-1 monitoring, and physician oversight matter more than the stack itself.
Frequently Asked Questions
Can you stack tesamorelin and sermorelin together?
You can physically combine them, but there is little pharmacological reason to do so. Both are GHRH analogs that bind the same pituitary receptor, so they compete for one target instead of adding a second pathway. No published human trial has tested the combination.
Is tesamorelin FDA-approved for weight loss?
No. Tesamorelin (Egrifta WR) is approved in the United States only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, bodybuilding, or anti-aging use.
What is a better alternative to a tesamorelin and sermorelin stack?
Pairing one GHRH analog with a ghrelin mimetic such as ipamorelin is the more common approach because it activates two different receptors. Adding a second GHRH analog, including CJC-1295, does not create a new pathway. A healthcare professional should review any protocol before use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.